MedTrace Logo

European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure

NCT00696631 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 653

Last updated 2010-02-15

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy, tolerability and safety of dronedarone versus placebo in patients with symptomatic congestive heart failure (CHF) and left ventricular dysfunction (LVD) when added to evidence based treatments for CHF.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

Dronedarone (SR33589)

oral administration

DRUG

Placebo

oral administration

Sponsors & Collaborators

Principal Investigators

  • ICD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2003-01-31
Completion
2003-08-31

Countries

  • Denmark
  • Hungary
  • Netherlands
  • Norway
  • Poland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00696631 on ClinicalTrials.gov